- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|Ajulemic acid (research code JBT-101) is being evaluated as a treatment for systemic lupus erythematosus (SLE) in Phase 2 clinical trial NCT03093402.
It was also more effective in reducing chronic neuropathic pain than placebo in a Phase 2 clinical trial .